Unc Lineberger Comprehensive Cancer Center

This study looks at whether giving money to clinics can encourage doctors to talk about and offer the HPV vaccine more often. Some clinics get training on how to talk about the vaccine, while others get the same training plus a financial reward and monthly progress reports. The g…

This phase II trial tests whether combining the immunotherapy drug durvalumab (Imfinzi) with radiation therapy can effectively treat intermediate-risk head and neck cancer after surgery, while causing fewer serious side effects than the standard cisplatin-based chemo-radiation. T…

This early-phase trial tests a new type of CAR-T cell therapy for people with relapsed or hard-to-treat acute lymphoblastic leukemia. The cells are engineered to recognize and kill leukemia cells, but also include a safety switch that can be turned on to calm them down if side ef…

This early-phase trial tests a new type of immunotherapy for people with Hodgkin lymphoma or cutaneous T-cell lymphoma that has returned or not responded to standard treatments. The therapy uses the patient's own T cells, which are genetically modified to recognize and attack can…

This study tests a drug called acalabrutinib in 10 people with central nervous system (CNS) lymphoma that has returned or not responded to treatment. The goal is to see if the drug is safe and can shrink tumors. Acalabrutinib is already approved for another type of lymphoma and w…

This study aimed to test a less intense version of a standard four-drug combination (Dara-RVd) for people newly diagnosed with multiple myeloma who are eligible for a stem cell transplant. The goal was to see if giving one drug (bortezomib) once a week instead of twice could stil…

This study tests a combination of three drugs—isatuximab, pomalidomide, and dexamethasone—at lower doses than usual. It includes 6 patients with multiple myeloma that has returned or not responded to treatment, who are also vulnerable due to age or other health problems. The goal…

This early-phase trial tests a new treatment for people with Hodgkin or non-Hodgkin lymphoma who have had a stem cell transplant. The treatment uses the patient's own T cells, which are modified in a lab to recognize and attack cancer cells that carry a protein called CD30. The m…

This early-phase trial tests a personalized vaccine (PANDA-VAC) made from a patient's own tumor markers, given alongside the immunotherapy drug pembrolizumab. It includes up to 6 people with advanced squamous cell lung cancer or head and neck cancer that cannot be cured. The main…

This early-phase pilot study is testing whether giving a PD-1 inhibitor (nivolumab or pembrolizumab) after CAR-T cell therapy can help people with relapsed or refractory classical Hodgkin lymphoma. The trial plans to enroll 10 adults whose cancer has not responded to at least thr…

This phase 2 trial tests a combination of two chemotherapy drugs (carboplatin and nab-paclitaxel) plus an immunotherapy drug (durvalumab) given before surgery for people with locally advanced head and neck cancer. The goal is to shrink or eliminate the tumor so that radiation—whi…

This study tests whether adding two drugs, pembrolizumab and olaparib, before and after standard chemoradiation can help control locally advanced head and neck cancer. About 45 adults with this cancer will receive the drug combination. The main goal is to see if this approach imp…

This study tests a new treatment for people with Hodgkin or non-Hodgkin lymphoma that has returned or not responded to standard therapy. The treatment involves taking a patient's own T cells (a type of immune cell), adding a gene that helps them recognize and attack lymphoma cell…

This early-phase study tests a new treatment for women with recurrent epithelial ovarian cancer. The therapy uses the patient's own immune cells, modified to find and attack cancer cells that carry a protein called B7-H3. The main goal is to check safety and find the best dose, w…

This early-phase study tests a new type of CAR T-cell therapy for people with B-cell lymphoma that has come back or not responded to treatment. The cells are engineered to target and kill cancer cells, but also include a safety switch that can be activated to reduce severe side e…

This study tests whether a standard two-day liver cancer treatment can be safely done in one day for patients with small tumors. The treatment uses tiny radioactive beads (Y90) to target cancer cells. Researchers will enroll 30 adults with small liver cancers to see if skipping a…

This early-phase study tests a new treatment for multiple myeloma that has come back or not responded to standard therapy. The treatment uses a patient's own immune cells (T cells) that are modified in the lab to recognize and attack cancer cells carrying a protein called CD138. …

This phase II trial tests the drug rituximab (Rituxan) as a first treatment for multicentric Castleman disease, a rare immune disorder, in 15 adults in Malawi. Some high-risk patients also receive etoposide. The study aims to see if rituximab is safe and works better than standar…

This study tests whether a mobile health tool called mPATH™-Cloud can help more people get screened for colorectal cancer. Over 1,000 patients from a community health center in North Carolina who are overdue for screening will either receive usual care or get a link to the tool, …

This trial tests whether training primary care clinics to better use HPV vaccine standing orders can increase vaccination rates in children ages 9-12. Some clinics receive communication training alone, while others also get help optimizing their standing orders. The study uses va…

This study aimed to see if using MRI scans to guide radiation away from the main saliva ducts could reduce dry mouth in people with oropharynx cancer. The trial planned to compare standard radiation with a new approach that spares these ducts. However, the study was withdrawn bef…

This study uses special MRI scans to see how radiation treatment affects the brain's white matter and thinking skills in people with cancer that has spread to the brain. Researchers will follow 15 patients to find early signs of memory or concentration problems. The goal is to be…

This study explores whether having kidney cancer patients report their side effects weekly through a short survey can help doctors manage those side effects better. The surveys ask about symptoms like nausea and fatigue and are sent directly to the care team, who then follow up i…

This study aims to see if it is practical to use electronic questionnaires to measure patient-reported symptoms before, during, and after radiation treatment for gynecologic cancer. About 100 English-speaking adults receiving radiation at UNC will participate. The main goal is to…

This pilot study aimed to see if a diet low in two specific nutrients (cysteine and methionine) could affect metabolism in patients with recurrent gliomas. Up to 30 participants were to be randomly assigned to either a normal diet or the special diet for 2, 4, or 7 days before st…

This study follows women who are cancer-free three or more years after early breast cancer treatment. Researchers want to see if things like patient traits, cancer type, or treatment side effects affect long-term quality of life. Participants fill out short questionnaires about e…

This study follows 127 people with HIV-related Kaposi sarcoma in Malawi and South Africa who are receiving standard chemotherapy (paclitaxel or bleomycin plus vincristine). Researchers want to understand why some patients respond better than others, looking at factors like gender…

This study was designed to track how the immune system recovers after CAR-T cell therapy and to test a pneumococcal vaccine (PCV-21) in these patients. It planned to enroll 50 adults with blood cancers or solid tumors. However, the study was withdrawn before any participants were…

This phase 2 trial is testing how the immunotherapy drug pembrolizumab (Keytruda) alone or with entinostat affects immune markers in people with muscle-invasive bladder cancer who cannot or choose not to have standard chemotherapy. Twenty participants receive the drugs before the…

This study aimed to see if a type of PET/MRI scan could predict which women with early endometrial cancer or a precancerous condition would respond to hormone therapy. It planned to enroll 8 women and follow them for 6 months. However, the study was withdrawn before any participa…

This study collects medical information and biological samples (blood, urine, stool, etc.) from 32 cancer patients starting or restarting immunotherapy. The goal is to build a research database to better understand why some patients develop immune-related side effects and how to …